PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
IPO Year: 2020
Exchange: NASDAQ
Website: ppd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/5/2021 | $47.50 | Neutral | Credit Suisse |
PPD, Inc. (NASDAQ:PPD), a leading global contract research organization, will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD's website at https://investors.ppd.com. An archived copy of the webcast will be available on the website after the call. In addition, the conference call can be accessed live over the phone by dialing +1 877 407 0784, or for international callers, +1 201 689 8560. A replay will be available after the call and can be accessed by dialing +1 844 5
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). The Company also announced that today, Moderna plans to request an Emergency Use Authorization (EUA) f
Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the
SC 13G - PPD, Inc. (0001793294) (Subject)
SC 13G - PPD, Inc. (0001793294) (Subject)
SC 13G - PPD, Inc. (0001793294) (Subject)
SC 13G - PPD, Inc. (0001793294) (Subject)
4 - PPD, Inc. (0001793294) (Issuer)
4 - PPD, Inc. (0001793294) (Issuer)
4 - PPD, Inc. (0001793294) (Issuer)
4 - PPD, Inc. (0001793294) (Issuer)
4 - PPD, Inc. (0001793294) (Issuer)
4 - PPD, Inc. (0001793294) (Issuer)
4 - PPD, Inc. (0001793294) (Issuer)
4 - PPD, Inc. (0001793294) (Issuer)
4 - PPD, Inc. (0001793294) (Issuer)
4 - PPD, Inc. (0001793294) (Issuer)
Key Takeaways: InnoCare Pharma’s A-share IPO will make it the fourth innovative pharma company with shares traded in Hong Kong and on the mainland’s STAR Market The company is flush with cash and continues to raise money at every opportunity to finance its R&D By Molly Wen China’s Nasdaq-style STAR Market has become fertile ground for fundraising by innovative yet profit-challenged pharmaceutical companies since its launch in 2019. Some 33 biomedical companies went public there last year alone, accounting for 20% of all new listings in 2021. That honey pot has attracted yet another taker from the pharma space, with InnoCare Pharma Ltd. (9969.HK) announcing it received the regulat
Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the
WALTHAM, Mass., Dec. 8, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (NASDAQ:PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. "We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapi
PPD, Inc. (NASDAQ:PPD) was named one of the "Best Workplaces in Greater China™ 2021" by Great Place to Work® for successfully creating an inclusive workplace experience for employees. PPD has more than 20 years of experience in the Asia-Pacific region, including providing a broad range of clinical development and laboratory services in Greater China. This is the second year PPD has received this recognition from Great Place to Work®, a global authority on high-trust, high-performance workplace cultures. "We remain committed to providing a healthy and open work environment for our employees, and this award shows that we continue to be successful in our efforts for yet another year," said D
PPD, Inc. (NASDAQ:PPD) was named "Best Vaccine CRO of the Year" at the Asia-Pacific Vaccine Excellence Awards 2021 for its strong presence, extensive experience and quality delivery in the Asia-Pacific (APAC) region. The award recognizes the contract research organization (CRO) operating within Asia that has engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality and safety in vaccine development and manufacturing. PPD accepted the award during a virtual ceremony at the third annual Vaccine World Asia Congress 2021, which attracted hundreds of representatives from Asia's top vaccine and supply chain companies. "This vaccine award furthe
PPD, Inc. (NASDAQ:PPD) earned numerous honors at the 2021 PharmaTimes Clinical Researcher of the Year-The Americas competition. Two PPD teams won gold, one team won silver and another team took home bronze. PPD clinical researchers also won silver and bronze awards in various individual categories. Last month, PPD was named "Clinical Research Company of the Year" at the 2021 PharmaTimes Clinical Researcher of the Year International competition in London. In addition to PPD winning the highest honor, a number of individual PPD clinical researchers also took home top honors in the individual categories during the international competition. "This award demonstrates that PPD's clinical resear
PPD, Inc. (NASDAQ:PPD), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2021. Highlights Net authorizations growth of 12.7% over third quarter 2020 to $1,352.7 million, resulting in a net book-to-bill ratio of 1.19x on a historical basis Ending backlog growth of 20.3% over third quarter 2020 to $9,492.5 million on a historical basis Revenue of $1,560.8 million, representing growth of 26.5% over third quarter 2020 Net income attributable to common stockholders of $152.9 million, compared to $52.0 million in thirdquarter 2020 Adjusted EBITDA of $280.3 million, compared to $232.6 million in third quarter
Funding Will Help Medable Accelerate Drug Development Through Decentralized Clinical Trials Medable Inc., the leading cloud platform for patient-centered clinical research, today announced $304 million in Series D funding to accelerate global adoption of digital and decentralized clinical trials, enabling ubiquitous access to the latest treatments for every body and every biology. The funding round was co-led by new investors Blackstone Growth and Tiger Global and existing investor GSR Ventures. The round also includes follow-on investment from existing investors Sapphire Ventures and WTI. This is Medable's fourth round of funding in 18 months, bringing total capital raised to $521 millio
PPD, Inc. (NASDAQ:PPD) was named "Clinical Research Company of the Year" at the 2021 PharmaTimes Clinical Researcher of the Year International competition in London. In addition to PPD winning the highest honor, individual PPD clinical researchers won gold and silver in both the Clinical Research Team and Start Up-Singles categories, as well as silver and bronze awards in the Aspiring Clinical Research Associate (CRA) category and bronze in the In-House CRA category. "This is the second year in a row that PPD has won this award, and we are thrilled that our clinical researchers continue to be recognized by PharmaTimes for their talent, work ethic and commitment to this industry year after
PPD, Inc. (NASDAQ:PPD), a leading global contract research organization, will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD's website at https://investors.ppd.com. An archived copy of the webcast will be available on the website after the call. In addition, the conference call can be accessed live over the phone by dialing +1 877 407 0784, or for international callers, +1 201 689 8560. A replay will be available after the call and can be accessed by dialing +1 844 5
PPD, Inc. (NASDAQ:PPD) is the recipient of the 2021 Eagle Award from the Society for Clinical Research Sites (SCRS) for its commitment to advancing clinical research professionalism through strong site partnerships. The award, based on voting by research sites globally, recognizes the contract research organization (CRO) that best exemplifies a site-focused approach to clinical trial management by demonstrating outstanding leadership, professionalism and integrity. "The Eagle Award is one of the most prestigious honors in our industry, and this recognition affirms PPD's ongoing commitment to create and sustain strong relationships with our site partners," said David Johnston, Ph.D., execu
15-12B - PPD, Inc. (0001793294) (Filer)
S-8 POS - PPD, Inc. (0001793294) (Filer)
8-K - PPD, Inc. (0001793294) (Filer)
25-NSE - PPD, Inc. (0001793294) (Subject)
10-Q - PPD, Inc. (0001793294) (Filer)
8-K - PPD, Inc. (0001793294) (Filer)
10-Q - PPD, Inc. (0001793294) (Filer)
8-K - PPD, Inc. (0001793294) (Filer)
DEFR14C - PPD, Inc. (0001793294) (Filer)
DEFM14C - PPD, Inc. (0001793294) (Filer)
Credit Suisse resumed coverage of PPD with a rating of Neutral and set a new price target of $47.50
JP Morgan downgraded PPD from Overweight to Neutral and set a new price target of $48.00
Jefferies downgraded PPD from Buy to Hold
Credit Suisse downgraded PPD from Outperform to Neutral and set a new price target of $47.50 from $42.00 previously
Evercore ISI Group downgraded PPD from Outperform to In-Line and set a new price target of $47.50 from $46.00 previously
Truist Securities downgraded PPD from Buy to Hold
Deutsche Bank downgraded PPD from Buy to Hold and set a new price target of $47.00 from $39.00 previously
William Blair downgraded PPD from Outperform to Market Perform
Keybanc downgraded PPD from Overweight to Sector Weight and set a new price target of $40.00
Baird downgraded PPD from Outperform to Neutral and set a new price target of $48.00